- Home
- LNKB vs ALXO Comparison
LNKB vs ALXO Comparison
Compare LNKB & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LNKB | ALXO |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 310.2M | 268.5M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LNKB | ALXO |
|---|---|---|
| Price | $8.30 | $1.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 91.2K | ★ 616.1K |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.61% | N/A |
| EPS Growth | ★ 26.76 | 26.36 |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $186,504,000.00 | N/A |
| Revenue This Year | $10.18 | N/A |
| Revenue Next Year | $9.33 | N/A |
| P/E Ratio | $9.22 | ★ N/A |
| Revenue Growth | ★ 11.29 | N/A |
| 52 Week Low | $6.09 | $0.41 |
| 52 Week High | $9.59 | $2.66 |
Technical Indicators
Market Signals| Indicator | LNKB | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 45.15 | 40.67 |
| Support Level | $8.07 | $1.41 |
| Resistance Level | $9.02 | $2.30 |
| Average True Range (ATR) | 0.21 | 0.16 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 49.06 | 22.58 |
Price Performance
Historical ComparisonAbout LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans. Company portfolio segments includes: Agriculture and farmland, Construction, Commercial & industrial, Commercial real estate, Residential real estate, Municipal, customers and Other loans.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.